Evidence map›Paper›PMID 25902705›Full record

Trial reportTrials2015

The Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trial.

Margaret Nampijja, Emily L Webb, James Kaweesa, Robert Kizindo, Milly Namutebi, Esther Nakazibwe, Gloria Oduru, Prossy Kabuubi, Joyce Kabagenyi, Dennison Kizito and 7 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. The Effect of Helminth Infections and Their Treatment on Metabolic Outcomes: Results of a Cluster-Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Allergen skin test reactivity and asthma are inversely associated with ratios of IgG4/IgE and total IgE/allergen-specific IgE in Ugandan communities.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Do helminth infections underpin urban-rural differences in risk factors for allergy-related outcomes?Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 4 countries.

Margaret NampijjaMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. maggie.nampijja@gmail.com.
Emily L WebbLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. emily.webb@lshtm.ac.uk.
James KaweesaVector Control Division, Ministry of Health, PO Box 1661, Kampala, Uganda. james.kaweesa@yahoo.co.uk.
Robert KizindoMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. kizindorobert@yahoo.com.
Milly NamutebiMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. namutebimilly49@yahoo.com.
Esther NakazibweEntebbe Hospital, PO Box 29, Entebbe, Uganda. esthersanyu22@gmail.com.
Gloria OduruMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. odurugloria@yahoo.com.
Prossy KabuubiMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. pkabubi2010@gmail.com.
Joyce KabagenyiMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. Joyce.Kabagenyi@mrcuganda.org.
Dennison KizitoMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. dennison.kizito@mrcuganda.org.
Lawrence MuhangiMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. Lawrence.Muhangi@mrcuganda.org.
Mirriam AkelloMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. mirriam_akello@yahoo.com.
Jaco J VerweijLaboratory for Medical Microbiology and Immunology, St Elisabeth Hospital, Postbus 90151, 5000 LC, Tilburg, the Netherlands. J.Verweij@elisabeth.nl.
Barbara NerimaUganda Virus Research Institute, PO Box 49, Entebbe, Uganda. bnerimanaomi@yahoo.com.
Edridah TukahebwaVector Control Division, Ministry of Health, PO Box 1661, Kampala, Uganda. edmuheki@gmail.com.
Alison M ElliottMRC/UVRI Uganda Research Unit on AIDS, PO Box 49, Entebbe, Uganda. alison.elliott@mrcuganda.org.
LaVIISWA trial team
Uganda Virus Research Institute · UGMinistry of Health · CYUniversity of London · GBNkumba University · UGSt. Elisabeth Hospital · CW

Funding

Medical Research Council MR/K012126/1Wellcome Trust 095778Wellcome Trust 100714
6 · The paper itself

Abstract

backgroundThe Hygiene Hypothesis proposes that infection exposure protects against inflammatory conditions. Helminths possess allergen-like molecules and may specifically modulate allergy-related immunological pathways to inhibit responses which protect against them. Mass drug administration is recommended for helminth-endemic communities to control helminth-induced pathology, but may also result in increased rates of inflammation-mediated diseases in resource-poor settings. Immunological studies integrated with implementation of helminth control measures may elucidate how helminth elimination contributes to ongoing epidemics of inflammatory diseases. We present the design of the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA), a cluster-randomised trial evaluating the risks and benefits of intensive versus standard anthelminthic treatment for allergy-related diseases and other health outcomes. METHODS/

designThe setting is comprised of island fishing communities in Mukono district, Uganda. Twenty-six communities have been randomised in a 1:1 ratio to receive standard or intensive anthelminthic intervention for a three-year period. Baseline characteristics were collected immediately prior to intervention rollout, commenced in February 2013. Primary outcomes are reported wheeze in the past 12 months and atopy (skin prick test response and allergen-specific immunoglobulin (asIg) E concentration). Secondary outcomes are visible flexural dermatitis, helminth infections, haemoglobin, growth parameters, hepatosplenomegaly, and responses to vaccine antigens. The trial provides a platform for in-depth analysis of clinical and immunological consequences of the contrasting interventions. DISCUSSION: The baseline survey has been completed successfully in a challenging environment. Baseline characteristics were balanced between trial arms. Prevalence of Schistosoma mansoni, hookworm, Strongyloides stercoralis and Trichuris trichiura was 52%, 23%, 13%, and 12%, respectively; 31% of Schistosoma mansoni infections were heavy (>400 eggs/gram). The prevalence of reported wheeze and positive skin prick test to any allergen was 5% and 20%, respectively. Respectively, 77% and 87% of participants had Dermatophagoides- and German cockroach-specific IgE above 0.35 kUA/L. These characteristics suggest that the LaVIISWA study will provide an excellent framework for investigating beneficial and detrimental effects of worms and their treatment, and the mechanisms of such effects.

trial registrationThis trial was registered with Current Controlled Trials (identifier: ISRCTN47196031) on 7 September 2012.

Indexed as

AlbendazoleAnimalsAnthelminticsBiomarkersClinical ProtocolsDermatitis, AtopicDrug Administration ScheduleHemoglobinsHost-Parasite InteractionsHumansImmunoglobulin EIntradermal TestsPraziquantelResearch DesignRespiratory HypersensitivityRespiratory SoundsAlbendazoleAnthelminticsBiomarkersHemoglobinsImmunoglobulin EPraziquantel

Identifiers

PMID25902705
PMCPMC4413531
OpenAlexW2128007468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.